Quantitative structure-activity relationships of some HIV-protease inhibitors

被引：15

作者：

Gupta, SP ^{[1
]}

Babu, MS ^{[1
]}

Kaw, N ^{[1
]}

机构：

[1] Birla Inst Technol & Sci, Pilani 333031, Rajasthan, India

来源：

JOURNAL OF ENZYME INHIBITION | 1999年 / 14卷 / 02期

关键词：

quantitative structure-activity relationship; HIV-1 protease inhibitors; cycloalkylpyranones;

D O I：

10.3109/14756369909036549

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A quantitative structure-activity relationship (QSAR) study has been made on different series of cycloalkylpyranones acting as human-immunodeficiency-virus type 1 (HIV-1) protease inhibitors. The results suggest that the enzyme binding affinity of the: compounds would be favoured by a cyclooctyl ring, a 3-cyclopropylphenylmethyl substituent at the pyranone ring, and a 4-CN-2-pyridine-, an N-Me-imidazole-, or a 3- or 4-CN-phenyl-sulfonamide group at the meta position of the phenyl ring of the 3-substituent.

引用

页码：109 / 123

页数：15

共 23 条

[1]

Appelt Krzysztof, 1993, Perspectives in Drug Discovery and Design, V1, P23, DOI 10.1007/BF02171654

[2]

Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X

[3] STUDIES ON STRUCTURE-ACTIVITY RELATIONSHIP .3. STRUCTURE-ACTIVITY STUDY OF PHENETHYLAMINES AS SUBSTRATES OF BIOSYNTHETIC ENZYMES OF SYMPATHETIC TRANSMITTERS [J].

FUJITA, T ;

BAN, T .

JOURNAL OF MEDICINAL CHEMISTRY, 1971, 14 (02) :148-&

[4]

GRIM H, 1973, BIOSTATICS PHARM, V2, pCH12

[5] RHO-SIGMA-PI ANALYSIS . METHOD FOR CORRELATION OF BIOLOGICAL ACTIVITY + CHEMICAL STRUCTURE [J].

HANSCH, C ;

FUJITA, T .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1964, 86 (08) :1616-&

[6]

Hansch C., 1995, Exploring QSAR-Fundamentals and Applications in Chemistry and Biology

[7] CHARACTERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 MUTANTS WITH DECREASED SENSITIVITY TO PROTEINASE-INHIBITOR RO-31-8959 [J].

JACOBSEN, H ;

YASARGIL, K ;

WINSLOW, DL ;

CRAIG, JC ;

KROHN, A ;

DUNCAN, IB ;

MOUS, J .

VIROLOGY, 1995, 206 (01) :527-534

[8] ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].

KOHL, NE ;

EMINI, EA ;

SCHLEIF, WA ;

DAVIS, LJ ;

HEIMBACH, JC ;

DIXON, RAF ;

SCOLNICK, EM ;

SIGAL, IS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690

[9] DIASTEREOSELECTIVE SYN-EPOXIDATION OF 2-ALKYL-4-ENAMIDES TO EPOXYAMIDES - SYNTHESIS OF THE MERCK HIV-1 PROTEASE INHIBITOR EPOXIDE INTERMEDIATE [J].

MALIGRES, PE ;

UPADHYAY, V ;

ROSSEN, K ;

CIANCIOSI, SJ ;

PURICK, RM ;

ENG, KK ;

REAMER, RA ;

ASKIN, D ;

VOLANTE, RP ;

REIDER, PJ .

TETRAHEDRON LETTERS, 1995, 36 (13) :2195-2198

[10] CONCEPTS AND PROGRESS IN THE DEVELOPMENT OF PEPTIDE MIMETICS [J].

OLSON, GL ;

BOLIN, DR ;

BONNER, MP ;

BOS, M ;

COOK, CM ;

FRY, DC ;

GRAVES, BJ ;

HATADA, M ;

HILL, DE ;

KAHN, M ;

MADISON, VS ;

RUSIECKI, VK ;

SARABU, R ;

SEPINWALL, J ;

VINCENT, GP ;

VOSS, ME .

JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (21) :3039-3049

← 1 2 3 →